慢阻肺相关呼气中央气道塌陷:当前概念与新视角
本综述系统评估慢阻肺相关呼气中央气道塌陷(ECAC)的流行病学、病因、病理生理、临床表现、诊断和治疗。支气管镜是诊断金标准,动态双相CT为替代无创方法;无创通气可长期使用,临时支架缓解急性重度气管支气管软化,气管支气管成形术疗效确切但围术期并发症需重视。未来需随机对照试验、成本效果分析和共识指南。
要点
- 慢阻肺相关ECAC常被忽视,症状不典型,发病率与发病机制未知。
- 支气管镜是诊断金标准,动态双相CT可作为替代无创方法。
- 无创通气可长期使用,临时支架缓解急性重度软化,长期支架需评估风险获益。
核心结论
- 慢阻肺相关ECAC的病理生理机制、诊断和管理仍充满挑战。
- 未来亟需以患者为中心结局的随机对照试验、不同干预的成本效果分析和共识指南。
研究设计与样本
- 综述系统评估慢阻肺相关ECAC的流行病学特征、病因、病理生理特点、临床表现、诊断和治疗。
主要发现
- 慢阻肺相关ECAC是一种良性气道狭窄疾病,临床症状不典型,发病率和发病机制未知。
- 支气管镜是诊断金标准,动态双相CT成像是替代无创方法。
- 无创通气治疗可长期继续。
- 临时气道支架可缓解急性和重度气管支气管软化。
- 气管支气管成形术对重度气管支气管软化有确切疗效,但围术期并发症仍是严重问题,需长期疗效观察。
关键数值与推荐
- 支气管镜为诊断金标准,动态双相CT为替代无创方法。
- 长期支架植入需在风险获益评估后考虑。
临床怎么用
- 对慢阻肺患者应警惕ECAC,症状不典型时考虑支气管镜或动态双相CT诊断。
- 无创通气可用于长期治疗。
- 急性重度气管支气管软化可临时置入气道支架缓解。
- 长期支架植入需评估风险获益。
- 重度气管支气管软化可考虑气管支气管成形术,但需关注围术期并发症。
局限性
- 慢阻肺相关ECAC的发病率和发病机制未知。
- 中医药、其他正呼气压治疗和肺移植证据有限。
- 气管支气管成形术围术期并发症仍是严重问题,需长期疗效观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC IMPORTANCE: COPD-associated expiratory central airway collapse (ECAC) is a frequently overlooked benign airway obstructive disease with complex causes and unclear pathologic and physiologic mechanisms. Although interventions such as noninvasive positive pressure ventilation, airway stenting, and tracheobronchoplasty have shown definite efficacy in the treatment of COPD-associated ECAC, the diagnosis and treatment of this disease remain challenging. This review provides a systematic evaluation and outlook on the epidemiologic features, causes, pathophysiologic characteristics, clinical manifestations, diagnosis, and treatment of COPD-associated ECAC. REVIEW FINDINGS: COPD-associated ECAC is a benign airway narrowing disease with atypical clinical symptoms and unknown incidence and pathogenesis. Bronchoscopy is considered the gold standard technique for diagnosis of COPD-associated ECAC, with dynamic biphasic CT imaging as an alternative noninvasive method. Noninvasive ventilation treatment can be continued on a long-term basis. Temporary airway stents can alleviate acute and severe tracheobronchomalacia. Long-term stent implantation can be considered after a risk to benefit assessment. Although tracheobronchoplasty has a definite therapeutic effect in patients with severe tracheobronchomalacia, perioperative complications remain a serious issue, and long-term efficacy observation is required. Traditional chinese medicine, other positive expiratory pressure therapies, and lung transplantation have shown potential with limited evidence. SUMMARY: Although COPD-associated ECAC is attracting considerable attention, its pathophysiologic mechanisms, diagnosis, and management are full of challenges. In the future, randomized controlled trials on different therapies using patient-centered outcomes, cost-effective analysis on different interventions, and consensus guidelines on COPD-associated ECAC will be urgently needed.
引用
- Zhou P, Yu W, Zhang W, et al. COPD-Associated Expiratory Central Airway Collapse: Current Concepts and New Perspectives. Chest. 2024. PMID: 39580112. doi:10.1016/j.chest.2024.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。